
For the first time, doctors may be able to diagnose chronic traumatic encephalopathy — CTE — in a living person with a simple blood test. Two studies published in the Journal of the American Medical Association report that a protein marker in the blood, eMTBR-tau, was far higher in people with advanced CTE than in people with little or no sign of the disease. Until now, CTE could only be confirmed by examining the brain after death.
The findings, reported on November 19, 2026, could transform care, research and trials — though both teams stress the test is not ready for clinics yet.
Two research teams working independently reached the same conclusion: a blood marker can separate people with advanced CTE from people without it. The first team, from Boston University and Banner Health, studied 21 former American football players — 12 professional, seven college and two high school players — whose blood was drawn in life and whose brains were donated for examination after death. Eighteen had CTE, and 16 had high-stage disease, McKee stage 3 or 4. In those players, blood levels of eMTBR-tau were significantly higher than in players with low-stage CTE or no CTE.
The Washington University team studied 229 participants and found the related marker eMTBR-tau243 elevated in advanced CTE, rising with disease severity — the first consistent evidence that a blood test can track a disease invisible in life.
CTE is a degenerative brain disease linked to repeated head impacts, most famously in American football, but also in other contact sports and in military service. It is associated with memory loss, confusion, mood changes, depression and, in later stages, dementia. The disease is driven by the build-up of an abnormal form of the tau protein in the brain.
For families and for medicine, the cruelest feature of CTE has been its invisibility. A player could suffer for years with symptoms that looked like depression, early dementia or simply ageing, and no scan or test could say whether CTE was the cause. Confirmation came only at autopsy — so patients never got a certain diagnosis, doctors could never tailor treatment, and researchers could never be sure the people in their trials actually had CTE.
The search for a living test has run for years, through brain scans, spinal fluid and blood markers, with no result reliable enough for the clinic. The new studies focus on a fragment of tau itself — eMTBR-tau — that appears in the blood when the disease is advanced.
The test measures eMTBR-tau, a fragment of the tau protein, in a blood sample. In the Boston study, the marker was significantly higher in former players whose brains later showed high-stage CTE than in those with low-stage disease or none. The Washington study found the same pattern with eMTBR-tau243: levels were elevated in advanced CTE and climbed as the disease grew more severe.
That dose-response pattern — the worse the disease, the higher the marker — is what makes researchers hopeful. A marker that tracks severity could follow the disease over time and judge whether a treatment is working. But the test compares blood from living people against brain findings after death, so larger studies are needed before any clinic can offer it.
The researchers behind both studies describe the results as a breakthrough with limits. A commercial test could be available within five years, they say, but both studies are small and preliminary and need validation before clinical use. The Boston study followed only 21 former players, and the Washington study, at 229 participants, still needs repeating in bigger and more diverse groups.
That caution matters because a test for CTE would carry heavy consequences: a positive result could shape medical care, decisions about work and sport, and family planning. The marker also performed best in high-stage disease; whether it can catch CTE early, when treatment would matter most, is still open.
A reliable blood test would change the disease three ways at once. It would give patients and families an answer while there is still time to act. It would give doctors a way to distinguish CTE from conditions with similar symptoms, such as Alzheimer's disease or depression, which need very different treatment. And it would let researchers run proper clinical trials, enrolling people known to have CTE and measuring whether a drug slows it.
The stakes reach beyond football: CTE has been found in military veterans exposed to blasts, in boxers, ice hockey and rugby players, and in others with repeated head trauma. A blood test would let all of them be studied and, eventually, treated on evidence rather than guesswork.
The next step is validation: larger studies in more people, including women, non-athletes and people at earlier stages, to confirm the marker holds up outside the two original groups. If those succeed, the test would still need regulatory clearance — the researchers' estimate of a commercial test within five years reflects that path.
For anyone worried about CTE today, the advice has not changed: the test is not available, and no clinic can order it yet. People with symptoms after repeated head impacts should talk to their doctor. For readers following brain research, our earlier coverage includes a CAR-T therapy that wiped out deadly childhood brain tumours in every mouse tested and the obituary of Marsha Linehan, creator of dialectical behavior therapy.
What is CTE?
Chronic traumatic encephalopathy is a degenerative brain disease linked to repeated head impacts, associated with memory loss, mood changes and dementia, driven by abnormal tau protein in the brain.
How is CTE diagnosed today?
Only after death, by examining donated brain tissue. No scan or blood test can diagnose it in a living person.
What did the two new JAMA studies find?
That blood marker eMTBR-tau was significantly higher in high-stage CTE, and eMTBR-tau243 rose with disease severity — the first evidence a blood test can detect CTE in life.
When will the blood test be available?
Researchers say a commercial test could be available within five years, but both studies are small and preliminary and need validation and clearance first.
Who was studied?
Boston University and Banner Health studied 21 former American football players; Washington University studied 229 participants.